key: cord-0789688-ilo7klco
authors: Hu, Shiling; Wang, Jue; Zhang, Yongjing; Bai, Haoyun; Wang, Cheng; Wang, Nan; He, Langchong
title: Three salvianolic acids inhibit 2019‐nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2
date: 2021-02-19
journal: J Med Virol
DOI: 10.1002/jmv.26874
sha: 1c2e78056125a83f6bfe9ee370313d0263a5c7f6
doc_id: 789688
cord_uid: ilo7klco

Since December 2019, the new coronavirus (also known as severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2, 2019‐nCoV])—induced disease, COVID‐19, has spread rapidly worldwide. Studies have reported that the traditional Chinese medicine Salvia miltiorrhiza possesses remarkable antiviral properties; however, the anti‐coronaviral activity of its main components, salvianolic acid A (SAA), salvianolic acid B (SAB), and salvianolic acid C (SAC) is still debated. In this study, we used Cell Counting Kit‐8 staining and flow cytometry to evaluate the toxicity of SAA, SAB, and SAC on ACE2 (angiotensin‐converting enzyme 2) high‐expressing HEK293T cells (ACE2(h) cells). We found that SAA, SAB, and SAC had a minor effect on the viability of ACE2(h) cells at concentrations below 100 μM. We further evaluated the binding capacity of SAA, SAB, and SAC to ACE2 and the spike protein of 2019‐nCoV using molecular docking and surface plasmon resonance. They could bind to the receptor‐binding domain (RBD) of the 2019‐nCoV with a binding constant (K (D)) of (3.82 ± 0.43) e−6 M, (5.15 ± 0.64)e−7 M, and (2.19 ± 0.14)e‐6 M; and bind to ACE2 with K (D) (4.08 ± 0.61)e−7 M, (2.95 ± 0.78)e−7 M, and (7.32 ± 0.42)e−7 M, respectively. As a result, SAA, SAB, and SAC were determined to inhibit the entry of 2019‐nCoV Spike pseudovirus with an EC(50) of 11.31, 6.22, and 10.14 μM on ACE2(h) cells, respectively. In conclusion, our study revealed that three Salvianolic acids can inhibit the entry of 2019‐nCoV spike pseudovirus into ACE2(h) cells by binding to the RBD of the 2019‐nCoV spike protein and ACE2 protein.

Since December 2019, coronavirus disease (COVID-19) has been affecting global health and thus far, there has been no sign of the pandemic subsiding. As of August 28, 2020, more than 10 million people had been infected, with 830,057 deaths recorded worldwide. 1, 2 Patients infected with novel coronavirus (2019-nCoV; also known as severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) manifest many symptoms, such as dry cough, fever, headache, dyspnea, and pneumonia, with an estimated mortality rate ranging from 3% to 5%, which is lower than that in individuals infected with pathogenic SARS-CoV (2002) (2003) and Middle East respiratory syndrome coronavirus (MERS-CoV, 2012). [3] [4] [5] Therefore, it is urgent to develop an effective program for the prevention and treatment of COVID-19-associated pneumonia.

2019-nCoV is a positive-sense single-stranded RNA virus with a crown-like appearance due to the projection of surface spike glycoproteins (S proteins) from its envelope. 6 Coronaviruses use the homotrimeric S protein (comprised of an S1 subunit and S2 subunit in each spike monomer) on the envelope to bind to their cellular receptors. 6 This binding triggers a cascade of events that lead to the fusion of the cell and viral membranes, enabling entry into the cell. As with SARS-CoV, the receptor binding domain (RBD) of the 2019-nCoV S protein binds to the angiotensinconverting enzyme 2 (ACE2) cell receptor. [7] [8] [9] However, the RBD of 2019-nCoV has a higher binding affinity for ACE2 than that of SARS-CoV. 6 RBDs of S proteins of SARS-CoV or 2019-nCoV can both be used as vaccines to induce the production of crossreactive or cross-neutralizing antibodies for preventing viruses from entering their target cells expressing its receptor ACE2. 10 Similarly, the S protein can also be used as a target for the creation of a COVID-19 vaccine. Such vaccines can be based on the 2019-nCoV full-length S protein and its RBD; moreover, vaccines could be based on DNA, viral vectors and subunits. 11 A candidate messenger RNA vaccine stabilized the coronavirus S proteins by substituting two prolines at the top of heptad repeat 1, thereby preventing structural rearrangements of the fusion (S2) subunit, and successfully induced anti 2019-nCoV immune responses in all participants. 12 Salvianolic acid A (SAA), salvianolic acid B (SAB), and salvianolic acid C (SAC) are phenolic carboxylic acids obtained from the aqueous extracts of Salvia miltiorrhiza. SAA, SAB, and SAC, which are major bioactive constituents of S. miltiorrhiza have been reported to have anticancer, anti-inflammatory, and cardioprotective effects. [13] [14] [15] [16] S. miltiorrhiza exhibits inhibitory effects against hepatitis B, hepatitis C, and SARS-CoV viruses. [17] [18] [19] Although no drug has been confirmed to be effective in inhibiting 2019-nCoV, treatment of COVID-19 symptoms is still remarkable in clinic. 20, 21 This is partly due to traditional Chinese medicine (TCM). 22, 23 Salvia miltiorrhiza is one of the five main components of Xuebijing (XBJ) which is a five-herb combined TCM, and other four components are Carthamus tinctorius, radix paeoniae rubra, Ligusticum wallichii, and Angelica sinensis. XBJ is widely used in China due to its anti-inflammatory and antiendotoxin effects. A clinical study has shown that XBJ significantly improves the pneumonia severity index of patients with severe community-acquired pneumonia. 24 

ACE2 h cells were constructed by Genomeditech. ACE2 h cells were maintained in DMEM high glucose medium containing 10% FBS, 1% penicillin-streptomycin, 0.75 μg/ml puromycin and cultured at 37°C in a 5% CO 2 incubator. 

To assess the surface plasmon resonance (SPR), the ACE2 protein with a 6-His tag (30 μg/ml) or SARS-CoV-2 spike S1 protein was fixed on a carboxyl sensor chip (Nicoya) via capture-coupling. Then, 12. Chemiluminescence was detected at 560 nm using a microplate reader, and the exposure time was 1 s.

Data are presented as the mean ± standard error of the mean (SEM) and were statistically analyzed using analysis of variance. Two-tailed tests were used for comparisons between two groups, and differences were considered statistically significant at p < .05. 

Based on the results of the study on the structure of ACE2, 9 we evaluated the binding abilities of SAA, SAB, and SAC to ACE2 using molecular docking and focused on whether SAA, SAB, and SAC could bind to ACE2. We found that SAA, SAB, and SAC all have good binding abilities, with respect to ACE2 protein ( Figure 4A ). Figure 4A shows that SAA binds to HIS34, which is an active site on the ACE2, Figure 4B ). These results further confirmed that SAB has a greater affinity for ACE2 than SAA and SAC.

The pseudovirus system is a classic model to study the entry process of enveloped viruses, as well as to assess the activity of antiviral agents targeting the virus entry stage. Here, we developed a Pseudovirus system using SARS-CoV-2 S protein to study the virus entry and tested SAA, SAB, and SAC on this assay. There are reports that chloroquine (CQ) can effectively treat COVID, and studies have shown that it can effectively inhibit the entry of the 2019-nCoV spike pseudovirus into ACE2 h cells. 27 Therefore, CQ was selected as the positive control for the experiment. The binding of 2019-nCoV with ACE2 is mediated mainly through polar interactions. 9 As with SARS-CoV, S1 subunits of 2019-nCoV contains the RBD, which directly binds to the peptidase domain (PD) of ACE2; whereas S2 is responsible for membrane fusion. 31, 32 An extended loop region of the RBD spans the arch-shaped α1 helix of ACE2-PD like a bridge. 9 The contact A key step in the viral infection process is the entry of viruses into cells. 27 

Angiotensin converting enzyme: a review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection

The trinity of COVID-19: immunity, inflammation and intervention

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells

Structure of the SARS-CoV-2 spike receptorbinding domain bound to the ACE2 receptor

COVID-19, ACE2, and the cardiovascular consequences

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

The spike protein of SARS-CoV--a target for vaccine and therapeutic development

SAC inhibited the entry of SARS-CoV-2 pseudovirus on ACE2 h cells. The experiments were repeat three times. Data are presented as mean ± SD

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation

An mRNA vaccine against SARS-CoV-2-preliminary report

Salvianolic acid A & B: potential cytotoxic polyphenols in battle against cancer via targeting multiple signaling pathways

Salvianolic acid A exhibits anti-inflammatory and antiarthritic effects via inhibiting NF-kappaB and p38/MAPK pathways

Salvia bowleyana Dunn root is a novel source of salvianolic acid B and displays antitumor effects against gastric cancer cells

Salvianolic acid A attenuates cerebral ischemia/ reperfusion injury induced rat brain damage, inflammation and apoptosis by regulating miR-499a/DDK1

Traditional Chinese medicine and related active compounds against hepatitis B virus infection

Effects of Chinese herbal medicine therapy on survival and hepatic outcomes in patients with hepatitis C virus infection in Taiwan

Tanshinones as selective and slow-binding inhibitors for Sars-Cov cysteine proteases

Drug repurposing against COVID-19: focus on anticancer agents

Hydroxychloroquine and azithromycin as a treatment of Covid-19: results of an open label non-randomized clinical trial

Contribution of traditional Chinese medicine to the treatment of COVID-19

Traditional Chinese medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP)

Xuebijing injection versus placebo for critically Ill patients with severe community-acquired pneumonia: a randomized controlled trial

Identification of the major constituents in Xuebijing injection by HPLC-ESI-MS

Rapid determination of 30 bioactive constituents in Xuebijing injection using ultra high performance liquid chromatography-high resolution hybrid quadrupole-orbitrap mass spectrometry coupled with principal component analysis

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Salvianolic acid A, as a novel ETA receptor antagonist, shows inhibitory effects on tumor in vitro

Salvianolic acid B promotes osteogenesis of human mesenchymal stem cells through activating ERK signaling pathway

Salvianolic acid B attenuates mitochondrial stress against Abeta toxicity in primary cultured mouse neurons

Structure of SARS coronavirus spike receptor-binding domain complexed with receptor

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Frontiers of medicine

Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus

Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models

Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein